NCT01662713 (OFDI) is a NA clinical trial of OFDI in Non-Melanoma Skin Cancer (NMSC), sponsored by Massachusetts General Hospital.

Who is sponsoring NCT01662713?

NCT01662713 is sponsored by Massachusetts General Hospital.

What drugs are being tested in NCT01662713?

Interventions in NCT01662713: OFDI.

What condition does NCT01662713 study?

NCT01662713 studies Non-Melanoma Skin Cancer (NMSC).

Is NCT01662713 still recruiting?

NCT01662713 is currently completed. Last updated 15 March 2023.

Last reviewed 2023-03-15 · How we verify

NCT01662713: OFDI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optical Frequency Domain Imaging for Non-melanoma Skin Cancers

Completed NA Last updated 15 March 2023

What this trial tests

NA trial testing OFDI in Non-Melanoma Skin Cancer (NMSC) in 10 participants. Completed in 1 December 2019.

Timeline

1 March 2017

Primary endpoint
1 December 2019

1 December 2019

Quick facts

Lead sponsor	Massachusetts General Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	device feasibility
Enrollment	10
Start date	1 March 2017
Primary completion	1 December 2019
Estimated completion	1 December 2019
Sites	1 location across United States

Drugs / interventions tested

OFDI

Conditions studied

Non-Melanoma Skin Cancer (NMSC) — all drugs for Non-Melanoma Skin Cancer (NMSC) →

Sponsor

Massachusetts General Hospital

Who can join

Adults 18 to 80, any sex, with Non-Melanoma Skin Cancer (NMSC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research study is to find out if a non-invasive imaging device called Optical Frequency Domain Imaging (OFDI) can help doctors to see the tissue and blood vessels that are related to non-melanoma skin cancers. OFDI was designed to see microscopic details of your skin without needing to use any invasive techniques such as surgery or biopsy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of OFDI

Trials testing the same drug.

NCT03292081 — Comparison Between OFDI and IVUS in PCI Guidance for Biolimus A9 Eluting Stent Implantation · Phase 2 · unknown

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01662713 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 15 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01662713.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing